Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003377 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
A Phase 1 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 13
- Study locations
NCT00003377 is a Phase 1 study of Cervical Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 29 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The trial reports 13 study locations across 8 states.
The verdict
NCT00003377, a Phase 1 study of Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 13
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel when given with radiation therapy and cisplatin and to see how well they work in treating patients with cancer of the cervix that has spread to the lymph nodes in the pelvis and abdomen.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- RADIATION brachytherapy
Study Locations (13)
Ohio
- MetroHealth's Cancer Care Center at MetroHealth Medical Center - Cleveland
- Cleveland Clinic Cancer Center at Fairview Hospital - Cleveland
- Cleveland Clinic Taussig Cancer Center - Cleveland
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University - Columbus
- Riverside Methodist Hospital Cancer Care - Columbus
Oklahoma
- Oklahoma University Medical Center - Oklahoma City
- Cancer Care Associates - Midtown Tulsa - Tulsa
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Illinois
- University of Chicago Cancer Research Center - Chicago
Iowa
- Holden Comprehensive Cancer Center at University of Iowa - Iowa City
New Jersey
- Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees - Camden
North Carolina
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1999-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003377
The ClinicalTrials.gov registry entry for NCT00003377 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00003377 reports 13 study locations spanning 8 distinct geographic areas - top geographies include Ohio, Oklahoma, Florida.
Frequently Asked Questions
What is clinical trial NCT00003377 about?
NCT00003377 is a clinical study titled "Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they ...
What is the current status of trial NCT00003377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 1999-11. Estimated completion is 2009-07.
What conditions does trial NCT00003377 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT00003377?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT00003377?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003377 being conducted?
This trial has 13 study locations across Florida, Illinois, Iowa, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.